Evidence map›Paper›PMID 33187537›Full record

ArticleJournal of translational medicine2020

DLDTI: a learning-based framework for drug-target interaction identification using neural networks and network representation.

Yihan Zhao, Kai Zheng, Baoyi Guan, Mengmeng Guo, Lei Song, Jie Gao, Hua Qu, Yuhui Wang, Dazhuo Shi, Ying Zhang

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Translational signaling and systems biology.Journal of translational medicine · 2021
    Article
  9. Comprehensive Survey of Recent Drug Discovery Using Deep Learning.International journal of molecular sciences · 2021
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Yihan ZhaoDepartment of Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Kai ZhengSchool of Computer Science and Engineering, Central South University, Changsha, China.
Baoyi GuanNational Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, Cardiovascular Diseases Center, China Academy of Chinese Medical Sciences, Beijing, China.
Mengmeng GuoInstitute of Cardiovascular Sciences, Health Science Center, Peking University, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing, China.
Lei SongDepartment of Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Jie GaoNational Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, Cardiovascular Diseases Center, China Academy of Chinese Medical Sciences, Beijing, China.
Hua QuNational Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, Cardiovascular Diseases Center, China Academy of Chinese Medical Sciences, Beijing, China.
Yuhui WangInstitute of Cardiovascular Sciences, Health Science Center, Peking University, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing, China.
Dazhuo ShiNational Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, Cardiovascular Diseases Center, China Academy of Chinese Medical Sciences, Beijing, China. shidztcm@163.com.
Ying ZhangNational Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, Cardiovascular Diseases Center, China Academy of Chinese Medical Sciences, Beijing, China. echo993272@sina.com.ORCID 0000-0002-7549-3968
Chinese Academy of Medical Sciences & Peking Union Medical College · CNBeijing University of Chinese Medicine · CNPeking University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDrug repositioning, the strategy of unveiling novel targets of existing drugs could reduce costs and accelerate the pace of drug development. To elucidate the novel molecular mechanism of known drugs, considering the long time and high cost of experimental determination, the efficient and feasible computational methods to predict the potential associations between drugs and targets are of great aid.

methodsA novel calculation model for drug-target interaction (DTI) prediction based on network representation learning and convolutional neural networks, called DLDTI, was generated. The proposed approach simultaneously fused the topology of complex networks and diverse information from heterogeneous data sources, and coped with the noisy, incomplete, and high-dimensional nature of large-scale biological data by learning the low-dimensional and rich depth features of drugs and proteins. The low-dimensional feature vectors were used to train DLDTI to obtain the optimal mapping space and to infer new DTIs by ranking candidates according to their proximity to the optimal mapping space. More specifically, based on the results from the DLDTI, we experimentally validated the predicted targets of tetramethylpyrazine (TMPZ) on atherosclerosis progression in vivo.

resultsThe experimental results showed that the DLDTI model achieved promising performance under fivefold cross-validations with AUC values of 0.9172, which was higher than the methods using different classifiers or different feature combination methods mentioned in this paper. For the validation study of TMPZ on atherosclerosis, a total of 288 targets were identified and 190 of them were involved in platelet activation. The pathway analysis indicated signaling pathways, namely PI3K/Akt, cAMP and calcium pathways might be the potential targets. Effects and molecular mechanism of TMPZ on atherosclerosis were experimentally confirmed in animal models.

conclusionsDLDTI model can serve as a useful tool to provide promising DTI candidates for experimental validation. Based on the predicted results of DLDTI model, we found TMPZ could attenuate atherosclerosis by inhibiting signal transductions in platelets. The source code and datasets explored in this work are available at https://github.com/CUMTzackGit/DLDTI .

Indexed as

Pharmaceutical PreparationsPhosphatidylinositol 3-KinasesAlgorithmsDrug RepositioningNeural Networks, ComputerSoftwarePharmaceutical PreparationsPhosphatidylinositol 3-KinasesAtherosclerosisDeep convolutional neural networksDrug-target interactionHeterogeneous informationNetwork representation learningStacked auto-encoder

Identifiers

PMID33187537
PMCPMC7666529
OpenAlexW3102745472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.